Infrascan's mobile bleed scanner wins FDA de novo approval to help first responders detect brain bleeds at an injury site.
Infrascan's handheld scanner landed FDA de novo approval to help first responders detect brain bleeds in patients who have undergone a traumatic head injury.
The Infrascanner Model 1000 uses near-infrared imaging to detect bleeds at an injury site within the "golden hour," the period following head trauma when pre-hospital analysis is critical.
"While patients with suspected brain injuries routinely receive a CT scan, this portable device offers emergency room physicians a non-invasive mechanism to aid in assessing whether an immediate CT scan is needed," Christy Foreman, of the FDA's Center for Devices & Radiological Health, said in prepared remarks.
The federal watchdog agency approved the Infrascanner through the "de novo" classification process, a pathway designed for low-risk medical devices that can't be compared to devices currently on the market.
In a 383-patient study, the Philadelphia-based company's handheld scanner detected nearly 75 percent of brain bleeds detected by a computed tomography scan. When CT scans detected no hematoma, neither did the Infrascanner 82 percent of the time.
The federal watchdog agency stressed that the Infrascanner Model 1000 is not a replacement for a standard CT scan.
Halloran expands clinical finance services and licenses leading industry financial forecasting tool...
Share prices tick up for C.R. Bard after it reports a 1st-quarter earnings beat.
Here's a look at some of the top legal news stories for medical device companies this week: Medtech...
Edwards Lifesciences CEO Michael Mussallem says the company now expects the FDA to approve its next-...
Reva Medical begins enrolling patients in Europe for a trial of its Fantom bioresorbable stent.